Maravai Lifesciences Holdings vs Schrodinger
Schrodinger is the larger business, with $256m of revenue in fiscal 2025 against $186m for Maravai Lifesciences Holdings (1.4 times as much). Schrodinger grew faster (23.3% against -28.3%). Schrodinger kept more of each dollar of sales as profit: a net margin of -40.4% against -70.4%. Schrodinger carries less debt relative to equity (0.0% against 138.5%).
| Latest fiscal year | Maravai Lifesciences HoldingsMRVI, 2025 | SchrodingerSDGR, 2025 |
|---|---|---|
| Revenue | $186m | $256m |
| Revenue growth | -28.3% | 23.3% |
| Net income | −$131m | −$103m |
| Operating margin | -115.9% | -65.2% |
| Net margin | -70.4% | -40.4% |
| Return on equity | -48.6% | -26.3% |
| Free cash flow | −$70.7m | $12.5m |
| Cash | $217m | $231m |
| Total debt | $294m | $0 |
| Debt to equity | 138.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 435 | 850 |
| Market value | $1.11bn | $2.05bn |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 20 sales |